Fractyl Health (GUTS) Operating Income (2023 - 2026)
Fractyl Health (GUTS) reported Operating Income of -$20.8 million for Q1 2026, up 15.91% year-on-year from -$18.0 million in Q1 2025, and up 10.58% quarter-over-quarter from -$23.3 million in Q4 2025.
Fractyl Health (GUTS) has 4 years of Operating Income data on file, last reported at -$20.8 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 15.91% year-over-year to -$20.8 million; the trailing twelve-month figure through Mar 2026 stood at -$92.9 million (up 4.0% YoY), and the FY2025 full-year result was -$96.8 million, down 3.51% from the prior year.
- Operating Income for Q1 2026 stood at -$20.8 million, up from -$23.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$11.9 million in Q2 2023 and bottomed at -$26.1 million in Q2 2025.
- A 4-year average of -$20.2 million and a median of -$22.7 million in 2025 frame the typical range for Operating Income.
- Across the five-year window, Operating Income sank 94.21% in 2024 and gained 15.91% in 2026, its largest moves.
- Tracing GUTS's Operating Income over 4 years: stood at -$13.0 million in 2023, then sank by 94.21% to -$25.2 million in 2024, then increased by 7.64% to -$23.3 million in 2025, then gained by 10.58% to -$20.8 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$20.8 million, -$23.3 million, and -$22.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 642.90 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -3.82 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | -20.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.82 Mn |
| Dec 31, 2025 | -23.28 Mn |
| Sep 30, 2025 | -22.69 Mn |
| Jun 30, 2025 | -26.08 Mn |
| Mar 31, 2025 | -24.76 Mn |
| Dec 31, 2024 | -25.21 Mn |
| Sep 30, 2024 | -23.79 Mn |
| Jun 30, 2024 | -22.99 Mn |
| Mar 31, 2024 | -21.54 Mn |
| Dec 31, 2023 | -12.98 Mn |
| Sep 30, 2023 | -13.87 Mn |
| Jun 30, 2023 | -11.88 Mn |
| Mar 31, 2023 | -12.11 Mn |